Clene Announces $7.3 Million Registered Direct Offering and Concurrent Private Placements Priced at Market Under Nasdaq RulesGlobeNewsWire • 09/30/24
Clene Granted In-Person Meeting With FDA Senior Leadership to Discuss CNM-Au8 Biomarker and Related Clinical and Survival DataGlobeNewsWire • 09/16/24
Clene to Present at the H.C. Wainwright 26th Annual Global Investment ConferenceGlobeNewsWire • 09/03/24
Wall Street Analysts Think Clene (CLNN) Could Surge 873.45%: Read This Before Placing a BetZacks Investment Research • 08/29/24
Wall Street Analysts Believe Clene (CLNN) Could Rally 976.32%: Here's is How to TradeZacks Investment Research • 08/13/24
IBN Announces Latest Episode of The BioMedWire Podcast featuring Rob Etherington, CEO of Clene Inc.GlobeNewsWire • 08/08/24
Clene Reports Second Quarter 2024 Financial Results and Recent Operating HighlightsGlobeNewsWire • 08/07/24
Clene Announces Plans to Submit Briefing Book to the U.S. Food and Drug Administration in Connection with Granted Type C Interaction to Obtain FDA Feedback on Potential Pathway to Accelerated Approval for CNM-Au8® in ALSGlobeNewsWire • 07/11/24
Clene to Present at H.C. Wainwright's 5th Annual Neuro Perspectives Virtual ConferenceGlobeNewsWire • 06/24/24
Clene Presents Preliminary Data for CNM-Au8® as a Potential Treatment for Rett SyndromeGlobeNewsWire • 06/21/24
Clene Presents Extended Survival Data Through 3.5 Years and New NfL Responder Results with CNM-Au8® 30 mg Treatment from the HEALEY ALS Platform Trial Open Label Extension at the 2024 ENCALS MeetingGlobeNewsWire • 06/18/24
Clene Provides Update on Its NIH-Funded Expanded Access Program for CNM-Au8® in ALS (ACT-EAP)GlobeNewsWire • 05/28/24
Clene Reports First Quarter 2024 Financial Results and Recent Operating HighlightsGlobeNewsWire • 05/08/24
Evidence for Clene's CNM-Au8® as a Treatment for Repair and Remyelination in Multiple Sclerosis Presented in the Emerging Science Session at the 2024 American Academy of Neurology Annual MeetingGlobeNewsWire • 04/16/24
Clene Announces Peer-Reviewed Publication Characterizing the Protein Corona of the Investigational Neurodegenerative Disease Drug, CNM-Au8®GlobeNewsWire • 03/15/24
Clene Reports Full Year 2023 Financial Results and Recent Operating HighlightsGlobeNewsWire • 03/13/24
Clene Presents Clinical Results of CNM-Au8® 30mg Treatment From Visionary-MS Trial Long-Term Extension at Annual ACTRIMS Forum 2024GlobeNewsWire • 02/29/24